Baidu
map

Cell Death Dis:广州生物院发现基因治疗佐剂引发神经退化

2018-09-27 佚名 广州生物院

该研究发现,Polybrene作为广泛使用的基因治疗和感染的佐剂,在低剂量下引发神经退化:小鼠的体内实验表现出运动障碍伴随脑内神经死亡和胶质增生,而在人神经元中诱发浓度依赖性轴突串珠化和碎片化。这一神经毒性的机制是钙离子内流双向调控细胞器重塑:线粒体断裂,内质网片段化并和线粒体耦合,而启动神经退化。

9月20日,Cell Death & Disease 发表了中国科学院广州生物医药与健康研究院刘兴国课题组研究成果“Polybrene induces neural degeneration by bidirectional Ca2+ influx-dependent mitochondrial and ER–mitochondrial dynamics”(《聚凝胺启动钙内流介导的线粒体和内质网-线粒体动态改变引发神经退化》)。该研究发现,Polybrene作为广泛使用的基因治疗和感染的佐剂,在低剂量下引发神经退化:小鼠的体内实验表现出运动障碍伴随脑内神经死亡和胶质增生,而在人神经元中诱发浓度依赖性轴突串珠化和碎片化。这一神经毒性的机制是钙离子内流双向调控细胞器重塑:线粒体断裂,内质网片段化并和线粒体耦合,而启动神经退化。

Polybrene(聚凝胺,hexadimethrine bromide)早期作为过量肝素的中和剂在临床使用,但是高剂量引起致死性的肾毒性从而限制了作为肝素中和剂的临床应用。低剂量的polybrene可以中和细胞膜的电荷促进病毒感染,而被广泛用作病毒感染促进剂,应用范围包括病毒相关基因治疗的佐剂和实验室的病毒感染研究。但是低剂量的polybrene对组织特异性毒性并不清楚。

刘兴国课题组通过体内外模型研究了低剂量polybrene对神经系统的毒性。在体内方面,侧脑室注射polybrene造成小鼠行为学(运动障碍)和病理学(神经死亡和胶质增生)上的神经退行表型。在体外方面,polybrene会导致人诱导多能干细胞(iPSCs)分化来源的神经元出现退化。进一步发现polybrene激活VDCC门控的胞外钙内流,导致了神经元胞内钙浓度的异常升高;升高的胞内钙双向调控两种细胞器异常重塑:DRP1S616位磷酸化介导的线粒体断裂和代谢异常,内质网片段化并和线粒体耦合介导线粒体钙超载,从而启动神经退化。

该研究揭示polybrene在低浓度下具有神经毒性,提示注意polybrene在应用中的潜在毒性和对实验结果的干扰;同时向人们展示了亚细胞水平多种细胞器重塑互作与神经退化的关系,为神经退行相关疾病的治疗提供了新的可能靶标。

该研究获得国家重点研发项目、中科院、国家自然科学基金、广东省和广州市的经费支持。


Polybrene诱导神经退化

原始出处:Bao F, Shi H, Gao M, et al. Polybrene induces neural degeneration by bidirectional Ca2+ influx-dependent mitochondrial and ER-mitochondrial dynamics. Cell Death Dis. 2018 Sep 20;9(10):966.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1961152, encodeId=9fad1961152ec, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 01 11:35:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870881, encodeId=ba8418e08818b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 11 10:35:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012813, encodeId=e89a20128139a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Apr 06 01:35:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531445, encodeId=6d2615314451d, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Sep 29 13:35:00 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2019-03-01 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1961152, encodeId=9fad1961152ec, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 01 11:35:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870881, encodeId=ba8418e08818b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 11 10:35:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012813, encodeId=e89a20128139a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Apr 06 01:35:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531445, encodeId=6d2615314451d, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Sep 29 13:35:00 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1961152, encodeId=9fad1961152ec, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 01 11:35:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870881, encodeId=ba8418e08818b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 11 10:35:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012813, encodeId=e89a20128139a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Apr 06 01:35:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531445, encodeId=6d2615314451d, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Sep 29 13:35:00 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1961152, encodeId=9fad1961152ec, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 01 11:35:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1870881, encodeId=ba8418e08818b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 11 10:35:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012813, encodeId=e89a20128139a, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Apr 06 01:35:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531445, encodeId=6d2615314451d, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Sat Sep 29 13:35:00 CST 2018, time=2018-09-29, status=1, ipAttribution=)]
    2018-09-29 cy0328

相关资讯

首次RNAi基因治疗药物获得FDA批准用于治疗hATTR成年患者

美国食品和药物管理局于本周五批准Alnylam Pharmaceuticals的Onpattro(patisiran)用于治疗遗传性转甲状腺素淀粉样变性(hATTR)引起的多发性神经病变的成年患者,这是美国首个批准用于治疗该适应症的药物。同时该药物也是第一个获批的siRNA基因疗法。

肾上腺脑白质营养不良的Lenti-D基因治疗的全新数据将于SSIEM 2018研讨会上公布

bluebird生物近日宣布,其用于研究儿童肾上腺脑白质营养不良(CALD)患者的Lenti-D基因疗法的临床试验的最新数据将在2018年SSIEM研讨会上公布。正在进行的II/III期Starbeam研究(ALD-102)的更新数据将评估Lenti-D基因治疗在17岁及以下CALD患者中的有效性和安全性。该公司还将提供其正在进行的观察性研究(ALD-103)的同种异体造血干细胞移植(allo-H

Nat Rev Drug Discov:AAV基因治疗神经系统疾病的进展与挑战

8月10日,Nature Reviews上发表了一篇关于AAV基因治疗神经系统疾病的进展与展望,通讯作者是Voyager Therapeutics的首席科学官Dinah WY Sah。文中探讨了未来设计和开发治疗性AAV载体的关键考虑因素和挑战,并且列举了最近的临床进展。

Orchard筹集1.5亿美元推进基因治疗

英国生物技术公司Orchard Therapeutics已筹集1.5亿美元推进其基因治疗管线。

2018 专家共识:儿童接受嵌合抗原受体T细胞治疗管理指南

2017年,嵌合抗原受体(CAR)T细胞治疗儿童和青少年复发性和/或难治性CD19+的急性淋巴细胞白血病患者,成果美国首个获批的基因疗法。本文主要针对儿童接受CAR-T细胞治疗的相关内容提供指导建议。 

Regeneron和Bluebird Bio强强联手助力于T细胞疗法

Regeneron和Bluebird Bio宣布合作,将各自的技术平台共同应用于癌症新型免疫细胞疗法的开发。这两个公司的合作将充分利用Regeneron的VelociSuite平台在全人源抗体和肿瘤特异性T细胞受体(TCR)方面的专业知识,和Bluebird Bio在基因治疗和细胞疗法上的领先技术。

Baidu
map
Baidu
map
Baidu
map